Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study.

摘要: The purpose of this study was to determine the safety and efficacy anticonvulsant levetiracetam in treatment children with autism. A previous open-label autistic treated demonstrated effectiveness hyperactivity, impulsivity/aggression, mood lability. Twenty patients autism ranging from 5 17 years age were entered into a 10-week, placebo-controlled, double-blind trial versus placebo. mean maximum dosage for 862.50+/-279.19 mg/day. We evaluated global improvement Clinical Global Impression-Improvement (CGI-I) Scale aggression affective instability Aberrant Behavior Checklist (ABC) parent teacher ratings. measured repetitive behaviors using Children's Yale-Brown Obsessive-Compulsive (CY-BOCS) score impulsivity hyperactivity Conners' Rating Scale-Revised: Long Version teacher. No significant difference found between placebo groups comparing change CGI-I (t=0.350, d.f.=13.621, P=0.765), nor on ABC, CY-BOCS or scales. These findings suggest that does not improve behavioral disturbances autism, but are limited by small sample size lack stratification at baseline.